Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Anti-HER2 radioimmunotherapy.

M W Brechbiel¹, T A Waldmann

¹Radioimmune and Inorganic Chemistry Section, Radiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-1374, USA.

|February 3, 2005

Summary

Radioimmunotherapy using HER2/neu targeted antibodies shows promise for breast cancer treatment. Metallic radionuclides, like lead-212, offer improved efficacy over radio-iodine, enabling complete tumor eradication in preclinical models.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

First-in-human phase 0 study of <sup>111</sup>In-CHX-A"-DTPA trastuzumab for HER2 tumor imaging.

Journal of translational science·2019

Same author

Bifunctional aryliodonium salts for highly efficient radioiodination and astatination of antibodies.

Bioorganic & medicinal chemistry·2017

Same author

Investigation of the complexation of <sup>nat</sup>Zr(iv) and <sup>89</sup>Zr(iv) by hydroxypyridinones for the development of chelators for PET imaging applications.

Dalton transactions (Cambridge, England : 2003)·2017

Same author

Accumulation of indium-111-labeled human low density lipoprotein in the rabbit aorta: Implications for nuclear imaging of vascular lesions.

Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology·2015

Same author

212Pb-radioimmunotherapy potentiates paclitaxel-induced cell killing efficacy by perturbing the mitotic spindle checkpoint.

British journal of cancer·2013

Same author

Efficient bifunctional decadentate ligand 3p-C-DEPA for targeted α-radioimmunotherapy applications.

Bioconjugate chemistry·2011

Area of Science:

Oncology
Radiochemistry
Immunotherapy

Background:

HER2/neu overexpression in breast cancer correlates with poor prognosis.
HER2/neu is a key therapeutic target for breast cancer treatment.
Monoclonal antibodies (mAbs) targeting HER2/neu are under investigation for therapeutic applications.

Purpose of the Study:

To evaluate the efficacy of anti-HER2/neu monoclonal antibodies linked to radionuclides for breast cancer radioimmunotherapy.
To compare the effectiveness of different radionuclides and strategies for HER2/neu targeted radioimmunotherapy.

Main Methods:

Utilized murine human breast cancer xenograft models.
Investigated radio-iodinated anti-HER2/neu mAbs.
Evaluated metallic radionuclides (e.g., 90Y, 213Bi, 212Bi, 212Pb) linked to anti-HER2/neu mAbs.
Explored a pre-targeting strategy using streptavidin-biotin system.

Main Results:

Radio-iodinated mAbs were more effective than unarmed mAbs but did not achieve permanent tumor eradication.
Complete elimination of breast cancer xenografts was achieved using (212)Pb linked to an anti-HER2/neu mAb in an adjuvant setting.
Pre-targeting strategies are being developed to improve radiolabel delivery to tumor cells.

Conclusions:

HER2/neu is a highly attractive target for systemic radioimmunotherapy of breast cancer.
Metallic radionuclides offer advantages over radio-iodine for HER2/neu targeted radioimmunotherapy.
Further research is needed to overcome challenges in delivering radiolabels to solid tumors for effective treatment.

Related Experiment Videos